Citigroup reiterates rating on Inhibrx Biosciences amid CEO stock purchases
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reiterated a market perform rating for Inhibrx Biosciences. Separately, CEO Mark Lappe purchased 10,040 shares of Inhibrx Biosciences stock on October 14, 2026, at an average price of $84.56 per share. This purchase increased his total ownership to 745,588 shares, valued at approximately $63 million.
From dailypolitical.com
Why it matters
The CEO's acquisition of shares suggests internal confidence in the company's valuation. Citigroup's rating maintains a positive outlook on the BioPharma sector, which could influence investor demand for Inhibrx Biosciences stock.
Citigroup previously reiterated a positive rating on the BioPharma sector on October 7, 2026.
From dailypolitical.com
Who's involved
- CitigroupAmerican investment bank that reiterated the market perform rating.
Keep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup reaffirmed a market outperform rating for HealthEquity.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Citigroup reiterated a market perform rating, Bank of America restated an underperform rating, and Raymond James Financial started coverage for Omega Healthcare Investors, Inc.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
- Citigroup reaffirmed a buy rating on BTI shares, and Capital Research Global Investors acquired shares of BTI.